Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease

Alimentary Pharmacology & Therapeutics
G R D'HaensP Rutgeerts

Abstract

Glucocorticosteroids are used frequently for the treatment of relapses of Crohn's disease. To investigate the influence of the new topically active glucocorticosteroid budesonide in comparison with methylprednisolone on bone turnover in a randomized open trial. Twenty-nine patients received either budesonide (controlled ileal release formulation) 9 mg for 10 weeks, or methylprednisolone 32 mg (equivalent to 40 mg prednisone) orally for 3 weeks with subsequent tapering. Patients who completed the trial with methylprednisolone (n = 8) had suppression of serum osteocalcin (30.2 +/- 2.6 to 20.4 +/- 2.0 ng/mL. P < 0.01), whereas no changes in this parameter of bone synthesis were observed during budesonide treatment (n = 11) (34.8 +/- 3.1 to 33.0 +/- 3.5 ng/mL). Urinary pyridinolines and deoxypyridinolines, highly sensitive markers of bone degradation, did not change in either group. Short-term methylprednisolone therapy impairs osteoblast activity in patients with Crohn's disease whereas budesonide does not.

References

Jul 1, 1989·Digestive Diseases and Sciences·H VogelsangA Gangl
Apr 1, 1987·Gut·J E CompstonJ Rhodes
Jun 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·G WolbergT P Zimmerman
Jan 1, 1984·Calcified Tissue International·W PeckL V Avioli
Aug 4, 1983·The New England Journal of Medicine·D J Baylink
Sep 29, 1994·The New England Journal of Medicine·G R GreenbergT Persson
Sep 29, 1994·The New England Journal of Medicine·P RutgeertsH Lorenz-Meyer
Dec 1, 1993·Alimentary Pharmacology & Therapeutics·R LöfbergL Salde
Nov 1, 1993·Gastroenterology·W A KleinR S Fisher

❮ Previous
Next ❯

Citations

Feb 13, 2008·Inflammatory Bowel Diseases·Robert HeuschkelAnne Griffiths
Sep 12, 2000·Current Gastroenterology Reports·I Lopez, A L Buchman
May 11, 2002·Current Treatment Options in Gastroenterology·Alan L. Buchman
Feb 7, 2013·Best Practice & Research. Clinical Gastroenterology·Charles RandallGregory Constantine
Nov 9, 2000·Alimentary Pharmacology & Therapeutics·C PapiL Capurso
May 31, 2001·Alimentary Pharmacology & Therapeutics·E J SchoonR W Stockbrügger
Aug 17, 2002·Alimentary Pharmacology & Therapeutics·S V KaneB G Feagan
Oct 7, 2006·Current Opinion in Gastroenterology·S B Hanauer
Aug 24, 1999·Inflammatory Bowel Diseases·A L Buchman
Nov 25, 2005·Inflammatory Bowel Diseases·Naomi LeeDennis R Taaffe
Mar 19, 2013·Therapeutic Advances in Gastroenterology·Cosimo Prantera, Stefano Marconi
Jul 1, 2010·Therapeutic Advances in Chronic Disease·Sarah O'Donnell, Colm A O'Morain
Sep 10, 2004·Clinical Pharmacokinetics·Staffan Edsbäcker, Tommy Andersson
Feb 18, 2014·Drugs·Stephan R VavrickaGerhard Rogler
Jul 13, 2012·Journal of Crohn's & Colitis·Tiago NunesMiquel Sans
Sep 9, 2004·Alimentary Pharmacology & Therapeutics·N FranchimontE Louis
Aug 5, 2003·Alimentary Pharmacology & Therapeutics·W J Sandborn, B G Feagan
Jul 13, 2006·Annals of the New York Academy of Sciences·Michael PazianasGary R Lichtenstein
Aug 5, 2000·Baillière's Best Practice & Research. Clinical Rheumatology·F Lioté, P Orcel
Oct 13, 2011·Expert Opinion on Pharmacotherapy·Mario CottoneFilippo Mocciaro
Apr 15, 2015·Journal of Crohn's & Colitis·Sasha TalebanMindy J Fain
Oct 2, 2003·The Annals of Pharmacotherapy·Kristi N Hofer
May 17, 2017·Inflammatory Bowel Diseases·Geoffrey C NguyenGil Y Melmed
Jun 15, 2017·Expert Opinion on Drug Metabolism & Toxicology·Lukasz KwapiszBrian Feagan
Nov 24, 2004·Advanced Drug Delivery Reviews·Richard N Fedorak, Lana Bistritz
May 11, 2002·The American Journal of Gastroenterology·Yu-Xiao Yang, Gary R Lichtenstein
May 11, 2002·The American Journal of Gastroenterology·Maria Cino, Gordon R Greenberg
Dec 18, 2018·Journal of Cellular Biochemistry·Yajun LiYuqin Li
Jun 20, 2006·Scandinavian Journal of Gastroenterology. Supplement·R A van Hogezand, N A T Hamdy
Jan 19, 2019·Journal of the Canadian Association of Gastroenterology·M Ellen KuenzigCynthia H Seow
Mar 15, 2020·Journal of Crohn's & Colitis·Alexander M DorringtonTim Raine
Dec 28, 2019·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·Eukene RojoJavier Gisbert
Mar 21, 2001·Critical Reviews in Clinical Laboratory Sciences·R J FarrellM A Peppercorn
Aug 29, 2006·World Journal of Gastroenterology : WJG·Katja S RothfussKlaus R Herrlinger
Jun 4, 2015·The Cochrane Database of Systematic Reviews·Ali RezaieCynthia H Seow
May 16, 2017·Journal of Nephrology·Marc G VervloetUNKNOWN CKD-MBD working group of ERA-EDTA
Aug 20, 2019·World Journal of Clinical Cases·Dolores SgambatoMarco Romano

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.